Journal of Immunotherapy最新文献_第5页

Monocytes Provoke Breast Cancer Cells to Express PD-L1 via a Cell-to-Cell Interaction Involving CD44 and Moesin. 单核细胞通过涉及CD44和Moesin的细胞间相互作用刺激乳腺癌细胞表达PD-L1。

IF 2.9 4区医学

Journal of Immunotherapy Pub Date : 2026-02-01 Epub Date: 2025-11-13 DOI: 10.1097/CJI.0000000000000585

Saya Matsumoto, Tsunao Kishida, Shin-Ichiro Kotani, Kenta Yamamoto, Mano Horinaka, Shusuke Yasuda, Toshiyuki Sakai, Yasuto Naoi, Tetsuya Taguchi, Osam Mazda

{"title":"Monocytes Provoke Breast Cancer Cells to Express PD-L1 via a Cell-to-Cell Interaction Involving CD44 and Moesin.","authors":"Saya Matsumoto, Tsunao Kishida, Shin-Ichiro Kotani, Kenta Yamamoto, Mano Horinaka, Shusuke Yasuda, Toshiyuki Sakai, Yasuto Naoi, Tetsuya Taguchi, Osam Mazda","doi":"10.1097/CJI.0000000000000585","DOIUrl":"10.1097/CJI.0000000000000585","url":null,"abstract":"Abstract: Triple-negative breast cancers (TNBCs), especially metastatic recurrent TNBCs, have a poorer prognosis than many other breast cancers. In recent years, immunotherapy using immune checkpoint inhibitors has been conducted for TNBC patients. Although a limited proportion of patients show excellent response, about half of the patients do not significantly respond to the immunotherapy. Monocytes are the progenitors of macrophages that are most abundantly seen in the tumor microenvironment (TME), but the influence of monocytes on breast cancer cells (BCCs) has not been fully clarified. Thus, we examined whether monocytes prompted BCCs to express PD-L1. As results, BCCs expressed higher levels of PD-L1 and its mRNA after co-culture with monocytes. RNA sequencing analysis revealed overexpression of Moesin mRNA in the BCCs co-cultured with monocytes. siRNA-mediated knockdown of Moesin restored the increase in PD-L1 expression. An addition of CD44 antibody canceled the augmentation of PD-L1 expression caused by the co-culture, suggesting that Moesin and CD44 may be essentially involved in the cell-to-cell interaction between monocytes and BCCs to induce PD-L1 expression. These findings may suggest a novel machinery of tumor escape from anti-tumor immunity, potentially providing implications for improving immunotherapy against TNBCs that are resistant to current immune checkpoint blockade therapy.","PeriodicalId":15996,"journal":{"name":"Journal of Immunotherapy","volume":" ","pages":"37-44"},"PeriodicalIF":2.9,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145906010","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A Novel Imidazoquinoline With TLR 7/8, STING, and Inflammasome Activity Demonstrates Antitumor Efficacy in Mouse Melanoma and Neu-Driven Mammary Adenocarcinoma. 一种具有TLR 7/8、STING和炎性体活性的新型咪唑喹啉在小鼠黑色素瘤和新驱动的乳腺腺癌中显示出抗肿瘤功效。

IF 2.9 4区医学

Journal of Immunotherapy Pub Date : 2026-01-01 DOI: 10.1097/CJI.0000000000000571

Shubhmita Bhatnagar, Vishnu Revuri, Carmen Merali, Bingxin Wang, John R Schultz, Peter Larson, Daohai Yu, Swayam Prabha, Thomas S Griffith, David Ferguson, Salim Merali, Jayanth Panyam

{"title":"A Novel Imidazoquinoline With TLR 7/8, STING, and Inflammasome Activity Demonstrates Antitumor Efficacy in Mouse Melanoma and Neu-Driven Mammary Adenocarcinoma.","authors":"Shubhmita Bhatnagar, Vishnu Revuri, Carmen Merali, Bingxin Wang, John R Schultz, Peter Larson, Daohai Yu, Swayam Prabha, Thomas S Griffith, David Ferguson, Salim Merali, Jayanth Panyam","doi":"10.1097/CJI.0000000000000571","DOIUrl":"10.1097/CJI.0000000000000571","url":null,"abstract":"Activation of endosomal Toll-like receptors 7 and 8 in antigen-presenting cells typically results in the induction of type I interferons (IFN). We previously reported a series of imidazoquinolines that potently activate TLR7/8. The potency and selectivity of these compounds can be tuned via substitutions to the N1 and C2 positions of the tricycle. Furthermore, C2-alkyl substitutions that project into a hydrophobic pocket at the dimer interface of the receptor significantly affect TLR7 and TLR8 activities. In the current study, we show that these compounds induce the expression of IFN-γ, a type II IFN, in addition to the classic type I IFNs. To understand the mechanism of type II IFN induction, we utilized global proteomics to evaluate the effect of our lead TLR7/8 agonist 4-amino-1-(4-(aminomethyl)benzyl)-2-butyl-7-methoxycarbonyl-1 H -imidazo[4,5- c ]quinoline (558) on dendritic cells (DCs). These studies show 558 activated STING and inflammasome pathways, in addition to its effect on TLR7/8. Based on the multifactorial mechanism of action, we also investigated the therapeutic benefit of 558 as a single agent. The effect of 558 dosing on various immune cell populations was investigated in tumor-bearing and healthy mice. Further, the effect of 558 on tumor multiplicity and tumor burden was studied in the transgenic Balb- neu T mice, which develop neu-driven mammary adenocarcinomas. 558 reversed the tumor-induced declines in antitumor immune cells in the bone marrow and lymph nodes of tumor-bearing mice. In vivo studies showed that 558 significantly reduced the rate of tumor growth, likely due to enhanced DC activation in the lymph nodes and CD8 T cell infiltration into the tumor tissue.","PeriodicalId":15996,"journal":{"name":"Journal of Immunotherapy","volume":" ","pages":"1-14"},"PeriodicalIF":2.9,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144789312","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Wild-Type p53 Overexpression Inhibits DNA Damage Pathways and Reduces PD-L1 Expression in Prostate Cancer. 野生型p53过表达抑制DNA损伤途径并降低前列腺癌中PD-L1的表达。

IF 2.9 4区医学

Journal of Immunotherapy Pub Date : 2026-01-01 DOI: 10.1097/CJI.0000000000000573

Heng Zhang, Guojun Lu, Yang Hu, Qing Yang, Jiawei Jiang, Min Xu

{"title":"Wild-Type p53 Overexpression Inhibits DNA Damage Pathways and Reduces PD-L1 Expression in Prostate Cancer.","authors":"Heng Zhang, Guojun Lu, Yang Hu, Qing Yang, Jiawei Jiang, Min Xu","doi":"10.1097/CJI.0000000000000573","DOIUrl":"10.1097/CJI.0000000000000573","url":null,"abstract":"The DNA damage response (DDR) pathway is crucial in tumor development and metastasis, influencing the tumor microenvironment. This study explores how p53, encoded by TP53, regulates PD-L1 expression in prostate cancer (PCa) from clinical, cellular, and tissue perspectives. Clinical PCa samples were analyzed for PD-L1, PD-1, p53, and PARP1 protein expression. DU145 cells were transfected with plasmids to overexpress wild-type p53 (WT-p53) and PD-L1. Protein and mRNA levels were measured by western blotting and qRT-PCR. DNA damage was assessed by γH2AX staining and comet assays. Cell proliferation was evaluated by colony formation assays, and apoptosis was analyzed by flow cytometry. A mouse tumor model was established to monitor tumor growth. Protein levels, γH2AX, and DNA damage were measured in mouse tumor tissues. Analysis of clinical samples showed a significant negative correlation between p53 and PD-L1/PARP1 levels. In vitro and in vivo experiments confirmed that WT-p53 overexpression reduces γH2AX expression, inhibiting DDR pathway activation. This led to decreased PARP1 and PD-L1 expression, increased apoptosis, and suppressed PCa cell proliferation. This study demonstrates that WT-p53 inhibits the activation of the DDR pathway, thereby leading to the downregulation of PARP1 and PD-L1 protein expression. These findings provide a novel theoretical foundation and potential therapeutic targets for future PCa treatments and research.","PeriodicalId":15996,"journal":{"name":"Journal of Immunotherapy","volume":" ","pages":"15-24"},"PeriodicalIF":2.9,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144835269","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Complete Remission of Hepatocellular Carcinoma With Atezolizumab and Bevacizumab Following Prior B-cell Depletion. 阿特唑单抗和贝伐单抗在既往b细胞耗尽后完全缓解肝细胞癌。

IF 2.9 4区医学

Journal of Immunotherapy Pub Date : 2026-01-01 DOI: 10.1097/CJI.0000000000000583

Jen-Pei Huang, Chun-Kuang Tsai, Pei-Ying Hsieh, San-Chi Chen

{"title":"Complete Remission of Hepatocellular Carcinoma With Atezolizumab and Bevacizumab Following Prior B-cell Depletion.","authors":"Jen-Pei Huang, Chun-Kuang Tsai, Pei-Ying Hsieh, San-Chi Chen","doi":"10.1097/CJI.0000000000000583","DOIUrl":"10.1097/CJI.0000000000000583","url":null,"abstract":"Immune checkpoint inhibitors (ICIs) are established therapies for unresectable hepatocellular carcinoma (HCC), with atezolizumab/bevacizumab and durvalumab/tremelimumab demonstrating clinical efficacy. Beyond activating CD8+ T cells, anti-PD(L)-1 therapies stimulate humoral immunity through B-cell activation and tertiary lymphoid structures. However, ICIs can also cause immune-related adverse events (irAEs), some managed with anti-CD20 therapy, raising concerns about whether B-cell depletion impacts subsequent ICI efficacy. This report presents a novel case of dual malignancies-diffuse large B-cell lymphoma (DLBCL) and HCC-in a patient in their 70s successfully treated with sequential R-CHOP and atezolizumab/bevacizumab. Following 6 cycles of R-CHOP for DLBCL, the patient achieved a complete metabolic response but developed recurrent HCC. Flow cytometry revealed B-cell depletion and hypogammaglobulinemia after R-CHOP. Upon initiation of atezolizumab/bevacizumab, AFP levels rapidly declined, and complete tumor remission was confirmed. Notably, NK cell percentages increased following ICI therapy, suggesting enhanced immune activation. This case demonstrates that prior rituximab-induced B-cell depletion does not impair the efficacy of anti-PD-L1 therapy in HCC and highlights the potential role of NK cells in mediating antitumor immunity during immunotherapy.","PeriodicalId":15996,"journal":{"name":"Journal of Immunotherapy","volume":" ","pages":"25-28"},"PeriodicalIF":2.9,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12662147/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145329402","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The Administration of Cetuximab-Based Regimen as a Second Line After Pembrolizumab Among Incurable Head and Neck Squamous Cell Carcinoma Patients. 在无法治愈的头颈部鳞状细胞癌患者中，基于西妥昔单抗的方案作为派姆单抗后的二线治疗。

IF 2.9 4区医学

Journal of Immunotherapy Pub Date : 2026-01-01 DOI: 10.1097/CJI.0000000000000579

Noga Kurman, Ido Even-Tov, Ofir Zavdy, Eyal Yosefof

{"title":"The Administration of Cetuximab-Based Regimen as a Second Line After Pembrolizumab Among Incurable Head and Neck Squamous Cell Carcinoma Patients.","authors":"Noga Kurman, Ido Even-Tov, Ofir Zavdy, Eyal Yosefof","doi":"10.1097/CJI.0000000000000579","DOIUrl":"10.1097/CJI.0000000000000579","url":null,"abstract":"Abstract: In the last years, combination of Pembrolizumab and chemotherapy has become standard of care first-line treatment among advanced-stage or metastatic head and neck squamous cell carcinoma (HNSCC) patients. However, the response rate for this treatment is still low, and most patients eventually progress, creating an unmet need for a standard second-line treatment. We aim to describe our experience with HNSCC patients who progress on Pembrolizumab and are treated with Cetuximab with or without chemotherapy. We performed a retrospective review of HNSCC patients who experienced disease progression after Pembrolizumab therapy (with or without chemotherapy) and subsequently received Cetuximab-containing regimens as second-line treatment, at a university-affiliated tertiary care center between 2019 and 2023. The study cohort comprised 21 patients whose disease progressed after a Pembrolizumab-containing first-line regimen. (mean age at HNSCC diagnosis: 66.3±13.2 y). Primary sites of origin were predominantly the oral cavity (52.4%, n=11) and oropharynx (19%, n=4). Treatment outcomes were as follows: complete response (14.3%, n=3), partial response (38.1%, n=8), stable disease (19.1%, n=4), and progression of disease (28.6%, n=6). The overall response rate was 52.4%, with a disease control rate of 71.4%. Median progression-free survival was 7.3 months (range: 1-38.3 mo). Cetuximab-containing second-line regimens demonstrated promising efficacy in HNSCC patients who progressed on Pembrolizumab-based protocols, yielding favorable response rates and durable responses. These findings warrant further investigation through prospective clinical trials to establish consensus guidelines for this patient population.","PeriodicalId":15996,"journal":{"name":"Journal of Immunotherapy","volume":" ","pages":"29-35"},"PeriodicalIF":2.9,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145069731","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Integrated Genomic Analysis Identifies Clinically Relevant Molecular Subtypes and Disulfidptosis-Related Prognostic Signature of Gastric Cancer. 综合基因组分析鉴定胃癌临床相关分子亚型和双歧杆菌相关预后特征

IF 2.9 4区医学

Journal of Immunotherapy Pub Date : 2025-11-01 Epub Date: 2025-07-14 DOI: 10.1097/CJI.0000000000000570

Yatao Wang, Fengqin Guo, Wei Song, Yanliang Liu, Qijun Xiang

{"title":"Integrated Genomic Analysis Identifies Clinically Relevant Molecular Subtypes and Disulfidptosis-Related Prognostic Signature of Gastric Cancer.","authors":"Yatao Wang, Fengqin Guo, Wei Song, Yanliang Liu, Qijun Xiang","doi":"10.1097/CJI.0000000000000570","DOIUrl":"10.1097/CJI.0000000000000570","url":null,"abstract":"Disulfidptosis is a newly defined disulfide stress-induced cell death. However, there are gaps in the prognostic role of disulfidptosis-related genes (DRGs) and their correlation with the tumor microenvironment (TME) in gastric cancer (GC). In here, we systematically investigated DRG changes at genomic and transcriptional levels, prognostic value, and their expression patterns in GC. Fifteen DRGs were used to identify the different subtypes, and the differences in prognosis and immune infiltration among the subtypes were examined. We identified 3 distinct molecular subtypes and observed profound differences among the 3 subtypes in clinical outcomes and infiltrating immune cells. Subsequently, a disulfidptosis-related signature (DRG_score) was constructed based on the overlapped disulfidptosis phenotype-related differentially expressed genes and was verified in an external cohort. The multivariate analysis confirmed that the DRG_score serves as an independent prognostic indicator for GC, and then a nomogram was built to increase the clinical applicability of the DRG_score. Furthermore, significant variations were observed in the TME, expression of multiple immune checkpoints, microsatellite status, tumor mutational burden, and response to different chemotherapeutics among the 2 DRG_score groups. A low DRG_score implies more significant TME cell infiltration and better response to immunotherapy. In conclusion, we present a comprehensive overview of the DRG profile in GC and develop a novel signature for GC patients. These findings could help us better understand DRG in GC and provide a theoretical foundation for future studies targeting disulfidptosis in GC.","PeriodicalId":15996,"journal":{"name":"Journal of Immunotherapy","volume":" ","pages":"343-357"},"PeriodicalIF":2.9,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144626530","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Synergistic Effect of Anti-PD-L1 Treatment and CD8+ T-Cell Activating Nanotherapy in Pancreatic Ductal Adenocarcinoma Evaluated via 3D Mathematical Modeling. 通过三维数学模型评估抗pd - l1治疗和CD8+ t细胞激活纳米治疗在胰腺导管腺癌中的协同作用。

IF 2.9 4区医学

Journal of Immunotherapy Pub Date : 2025-11-01 Epub Date: 2025-07-18 DOI: 10.1097/CJI.0000000000000572

Dylan A Goodin, Tina Daunke, Silje Beckinger, Sandra Krüger, Christoph Röcken, Susanne Sebens, Hermann B Frieboes

{"title":"Synergistic Effect of Anti-PD-L1 Treatment and CD8+ T-Cell Activating Nanotherapy in Pancreatic Ductal Adenocarcinoma Evaluated via 3D Mathematical Modeling.","authors":"Dylan A Goodin, Tina Daunke, Silje Beckinger, Sandra Krüger, Christoph Röcken, Susanne Sebens, Hermann B Frieboes","doi":"10.1097/CJI.0000000000000572","DOIUrl":"10.1097/CJI.0000000000000572","url":null,"abstract":"Summary: Although targeting programmed cell death ligand 1 (PD-L1) has been ineffective in reducing pancreatic ductal adenocarcinoma (PDAC) burden in preclinical and clinical studies, it is unknown if increasing activated CD8+ T-cell numbers, independently or in combination with anti-PD-L1 therapeutics, would improve tumor response. To facilitate evaluation of novel combinatorial strategies targeting PDAC, this study developed a modeling framework to assess therapies targeting PD-L1 and T-cell activation. Chitosan nanoparticles (CNP) loaded with a model antigen have recently shown promising anti-tumor effects by increasing dendritic cell (DC) mediated T-cell activation in a murine PDAC model. Using these in vivo data, along with in vitro and primary and liver metastatic PDAC in situ data, a 3D continuum mixture model of PDAC was rigorously calibrated and solved through distributed computing. The model was applied to analyze the response to anti-PD-L1 and/or antigen-CNP therapies at primary and liver metastatic sites. The results show realistic evaluation of combination therapy targeting PDAC at primary and liver metastatic sites. With the given parameter set, the model projects that anti-PD-L1 therapy and antigen-CNP would synergistically decrease tumor burden at primary and liver metastatic sites to 53.2% and 58.4% of initial burden 5.0 and 5.2 days post-treatment initiation, respectively. Delaying antigen-CNP application 3 or 5 days after anti-PD-L1 and gemcitabine administration further limited metastatic PDAC to <50% of initial burden 15 days post-treatment initiation. In conclusion, the proposed modeling approach enables realistic evaluation of novel combinations of agents, with the goal to design improved PDAC therapy.","PeriodicalId":15996,"journal":{"name":"Journal of Immunotherapy","volume":" ","pages":"331-342"},"PeriodicalIF":2.9,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145080798","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Clinical Efficacy and Safety of Cadonilimab Immunotherapy in Advanced Cervical Cancer: A Retrospective Study. 卡多尼单抗免疫治疗晚期宫颈癌的临床疗效和安全性：一项回顾性研究。

IF 2.9 4区医学

Journal of Immunotherapy Pub Date : 2025-11-01 Epub Date: 2025-08-21 DOI: 10.1097/CJI.0000000000000574

Xiuchen Han, Minjie Fang, Huaming Tan, Minjie Wang, Yayan Zhou, Xiugui Sheng

{"title":"Clinical Efficacy and Safety of Cadonilimab Immunotherapy in Advanced Cervical Cancer: A Retrospective Study.","authors":"Xiuchen Han, Minjie Fang, Huaming Tan, Minjie Wang, Yayan Zhou, Xiugui Sheng","doi":"10.1097/CJI.0000000000000574","DOIUrl":"10.1097/CJI.0000000000000574","url":null,"abstract":"This multicenter retrospective study assessed the safety and antitumor activity of cadonilimab in patients with recurrent or metastatic cervical cancer, particularly those with negative PD-L1 expression. Patients received cadonilimab, with or without additional treatments like chemotherapy, bevacizumab, or radiotherapy, and were monitored every 3 weeks until disease progression or intolerable toxicity was observed. The study included 21 patients: 18 with recurrent/metastatic cervical cancer (Figo IB1-IIIC) and 3 with newly diagnosed advanced cervical cancer (Fig IVB). The median follow-up duration was 9.7 (IQR: 2.3-23.6) months, and the median number of treatment cycles for cadonilimab was 10. Six patients had PD-L1-positive expression, and 6 had PD-L1-negative expression. Two patients with newly diagnosed advanced cervical cancer and 3 with recurrent disease achieved complete response; 10 patients had a partial response, and 1 patient had stable disease. Objective response rates were 71.4% (15 of 21 patients) overall and 66.7% (4 of 6 patients) for patients with PD-L1-negative expression. Grade 3-4 treatment-related adverse events occurred in 33.3% of patients, while immune-related adverse events were all G1-2 and occurred in 2 (9.5%) patients. No patients discontinued treatment due to intolerable toxicities. The study concluded that cadonilimab-containing therapies showed promising results in terms of responses and survival outcomes, with a favorable safety profile.","PeriodicalId":15996,"journal":{"name":"Journal of Immunotherapy","volume":" ","pages":"358-364"},"PeriodicalIF":2.9,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144957039","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Integrated Analysis of Single-cell and Bulk RNA-Sequencing Identifies a Signature Based on Cancer-related Fibroblast Marker Genes to Predict Prognosis and Therapy Response in Lung Adenocarcinoma. 单细胞和整体rna测序的综合分析确定了基于癌症相关成纤维细胞标记基因的特征，以预测肺腺癌的预后和治疗反应。

IF 2.9 4区医学

Journal of Immunotherapy Pub Date : 2025-11-01 Epub Date: 2025-08-20 DOI: 10.1097/CJI.0000000000000577

Gengqiu Liu, Jiacheng Feng, Yufeng Huang, Junhang Zhang, Yong Li

{"title":"Integrated Analysis of Single-cell and Bulk RNA-Sequencing Identifies a Signature Based on Cancer-related Fibroblast Marker Genes to Predict Prognosis and Therapy Response in Lung Adenocarcinoma.","authors":"Gengqiu Liu, Jiacheng Feng, Yufeng Huang, Junhang Zhang, Yong Li","doi":"10.1097/CJI.0000000000000577","DOIUrl":"10.1097/CJI.0000000000000577","url":null,"abstract":"Cancer-related fibroblasts (CAFs), crucial in the tumor microenvironment, significantly influence tumorigenesis and extracellular matrix shaping. This study aimed to analyze the expression of CAF marker genes in lung adenocarcinoma (LUAD) and create a prognostic signature. We included 716 LUAD patients from different cohorts, conducting a comprehensive analysis of single-cell RNA sequencing data from the Gene Expression Omnibus (GEO) database, identifying 227 CAF marker genes. Using the Cancer Genome Atlas (TCGA) LUAD cohort, we developed a 3-gene prognostic signature, categorizing patients into high-risk and low-risk groups. The signature's predictive capability was validated across clinical subgroups and GEO cohorts. It was determined as an independent prognostic factor via univariate and multivariate analyses, leading to the construction of a nomogram for clinical prognosis prediction. Immune profile analysis indicated that high-risk patients exhibited immunosuppression and immune cell infiltration, while the tumor immune dysfunction and exclusion score suggested higher immunotherapy sensitivity in the low-risk group. In addition, high-risk patients showed greater sensitivity to several first-line chemotherapeutic drugs. The expression of hub genes was validated using quantitative real-time reverse transcription polymerase chain reaction (qRT-PCR) and the Human Protein Atlas (HPA). In conclusion, this study presented a novel prognostic signature for LUAD patients based on CAF marker genes, demonstrating strong predictive power for prognosis and treatment response.","PeriodicalId":15996,"journal":{"name":"Journal of Immunotherapy","volume":" ","pages":"365-378"},"PeriodicalIF":2.9,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12479067/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144883007","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pembrolizumab Induced Aortitis in a Patient With Head and neck Cancer: A Case Report. Pembrolizumab诱导的头颈癌患者的主动脉炎：1例报告。

IF 2.9 4区医学

Journal of Immunotherapy Pub Date : 2025-09-01 DOI: 10.1097/CJI.0000000000000567

Erum Zaidi, Ningjing Li, Harshit Khosla, Syed H Jafri

引用次数: 0